......LookN for Gold
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If you can find a number- I’ll try reaching out....
I think Cramer said buy $EARS as well
lol jk
$LEAS ~ got a starter .....
$CDIX ~ setting up for a run imo....
She’s thin for sure....no reason this one can’t run wild with the rest of them
$MKD ~ worth a peek imo
$CHUC ~ adding the dips
$ATNF ~
$GTT - got a starter here.....
$DXF - added a few more
Awesome update for GENE.....
$GENE~
Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing
https://www.otcmarkets.com/stock/GENE/news/story?e&id=1789752
$KODK ~ KODAK LAUNCHES WITH PIGMENT.INC B.V EUROPE KODACOLOR RDTG SERIES DIRECT TO GARMENT (DTG) INKS
https://www.kodak.com/en/company/press-release/kodak-launches-with-pigment-inc-b-v-europe-kodacolor-rdtg-series-direct-to-garment-dtg-inks
$KODK ~ KODAK LAUNCHES WITH PIGMENT.INC B.V EUROPE KODACOLOR RDTG SERIES DIRECT TO GARMENT (DTG) INKS
https://www.kodak.com/en/company/press-release/kodak-launches-with-pigment-inc-b-v-europe-kodacolor-rdtg-series-direct-to-garment-dtg-inks
I believe it- any update would be nice
***APM*** ~>>> Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4, a Small Molecule Drug for...
January 20 2021 - 06:00AM
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced that the company, through its wholly owned subsidiary, Aptorum International Limited, has received clearance from the Public Health Agency of Canada (Health Canada) regarding the Clinical Trial Application (CTA) to commence a Phase 1 study of ALS-4, an orally administered small molecule drug intended to treat infections caused by Staphylococcus aureus including MRSA.
Dr. Clark Cheng, Chief Medical Officer and Executive Director of Aptorum Group, commented, “The clearance of our CTA application for ALS-4 drug represents a significant milestone for the company and one of a number of targeted strategic goals for 2021. This milestone supports the transition of Aptorum Group to a clinical-stage company and reflects the potential of our scientific rigor and novel approach of our products. We are dedicated to delivering novel therapeutics in the field of growing unmet medical needs of infections starting with Staphylococcus aureus.”
The Phase 1 clinical trial is planned to be conducted in Canada and targeted to recruit up to 48 and 24 healthy volunteers for the single-ascending dose (SAD) and multiple- ascending dose (MAD) cohorts, respectively. The primary objective of the trial is to evaluate the safety and tolerability of SAD and MAD of ALS-4 administered orally to healthy subjects. The secondary objective is to assess the pharmacokinetic profile of SAD and MAD of ALS-4 administered orally to healthy subjects.
About ALS-4
As part of Aptorum Group’s Acticule infectious disease platform, ALS-4 is a novel orally administered first-in-class small molecule that was developed based on an anti-virulence approach targeting Staphylococcus aureus including MRSA. ALS-4 can potentially lessen antimicrobial resistance via lowering selection pressure and render the bacteria to become highly susceptible to the host’s immune clearance. ALS-4 is targeted for potential administration both on a standalone or a combined basis with other existing antibiotics such as vancomycin.
About Aptorum Group
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers (including orphan oncology indications). The pipeline of Aptorum is also enriched through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through programs such as the systematic screening of existing approved drug molecules and microbiome-based research platform for treatments of metabolic diseases. Aptorum also has projects focused on microbiome research and the commercialization of a natural supplement product targeted for women undergoing menopause and experiencing related symptoms.
For more information about Aptorum Group, please visit www.aptorumgroup.com.
$EARS 2.63 - massive volume(306 mil) on December 1, $6.60 hod. I wonder if the buyer at $6.60 will make at least 100% this year? Hmmmm
$UONEK - might be a runner with tmrws inauguration speech...chart is set imo
$OGI - looks primed for 2021
$GME ~ game over or party just starting? I’m thinking it’s only 11pm and GME has just walked through the door lol....much more upside to come
Done....
~>>> Cuomo Pitches Rapid Testing to Open Restaurants, Theaters
https://www.thenationalherald.com/archive_general_news_usa/arthro/cuomo_pitches_rapid_testing_to_open_restaurants_theaters-1570303/
That $1 print on $NEVDF the other day~>> doesn’t always happen but can be an indication of where it’s going....
Looks like we may see 00s in the near future.....
You still in Mikey?
$AMC related ~>>> Silver Lake raises $20 billion for buyout fund
https://www.reuters.com/article/idUSKBN29I2X8?edition-redirect=ca
Big short interest
52 week high $7.78
2018 was above $20.....
Life without the movie theatres???? Not happening, no way. Gift prices here imo
ACER 3.84
AMC ONTX APM OXBR
$APM $AMC $OXBR
$GENE - got a starter recently for a long hold. I see $20+ in the cards
$ATOS - wouldn’t be surprised to see this over $10 in 2021
Popular one $IDEX - definitely a lot of strength in these pullbacks last couple months, getting bought up quick. Might be worth a peek to go long on....
Ideanomics Announces MEG December and Q4 Sales Activity
https://finance.yahoo.com/news/ideanomics-announces-meg-december-q4-120000074.html
Ideanomics Announces MEG December and Q4 Sales Activity
https://finance.yahoo.com/news/ideanomics-announces-meg-december-q4-120000074.html
Thanks- and same to you this year!
Yeah it is- and market cap at 840k. Real curious to see how this one plays out.
$AMC gearing up for a nice move imo
All good- thanks
Someone posted a R/s is coming? When? Tia
Uhhh “yeah” I’d say so...
you’re in my top 3 best of the best.
$OCLG creeping along here
Haha....love it